ReviewCurrent psychiatry reports2016
Withdrawing Benzodiazepines in Patients With Anxiety Disorders.
Review in Current psychiatry reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2023Guideline
- Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don't Know.Drugs · 2026Review
- Anxiolytic Effects ofFoods (Basel, Switzerland) · 2025Article
- Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.Molecular psychiatry · 2024Review
- A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- A Comprehensive Review of Essential Oils and Their Pharmacological Activities in Neurological Disorders: Exploring Neuroprotective Potential.Neurochemical research · 2024Review
- Production of Bi-Compartmental Tablets by FDM 3D Printing for the Withdrawal of Diazepam.Pharmaceutics · 2023Article
- Is the Precipitation of Anxiety Symptoms Associated with Bolus Doses of Flumazenil a Barrier to Its Use at Low Continuous Doses in Benzodiazepine Withdrawal?Journal of clinical medicine · 2022Article
- Surviving Benzodiazepines: A Patient's and Clinician's Perspectives.Advances in therapy · 2022Article
- Mobile phone applications to support psychotropic tapering: a scoping review protocol.HRB open research · 2022Article
- Article
- Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.BMC medicine · 2020Review
- Novel Therapeutic Approach for the Management of Mood Disorders: In Vivo and In Vitro Effect of a Combination of L-Theanine,Nutrients · 2020Article
- Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review.Advances in therapy · 2020Review
- Tinnitus associated with benzodiazepine withdrawal syndrome: A case report and literature review.The mental health clinician · 2020Article
- Benzodiazepine Prescribing in People with Chronic Obstructive Pulmonary Disease: Clinical Considerations.Drugs & aging · 2020Review
- Pharmacological Evaluation ofEvidence-based complementary and alternative medicine : eCAM · 2018Article
- Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety.Biological psychiatry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The large class of CNS-depressant medications-the benzodiazepines-have been extensively used for over 50 years, anxiety disorders being one of the main indications. A substantial proportion (perhaps up to 20-30 %) of long-term users becomes physically dependent on them. Problems with their use became manifest, and dependence, withdrawal difficulties and abuse were documented by the 1980s. Many such users experience physical and psychological withdrawal symptoms on attempted cessation and may develop clinically troublesome syndromes even during slow tapering. Few studies have been conducted to establish the optimal withdrawal schedules. The usual management comprises slow withdrawal over weeks or months together with psychotherapy of various modalities. Pharmacological aids include antidepressants such as the SSRIs especially if depressive symptoms supervene. Other pharmacological agents such as the benzodiazepine antagonist, flumazenil, and the hormonal agent, melatonin, remain largely experimental. The purpose of this review is to analyse the evidence for the efficacy of the usual withdrawal regimes and the newer agents. It is concluded that little evidence exists outside the usual principles of drug withdrawal but there are some promising leads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.